Skip to main content

Clinical Trials Using Tisagenlecleucel

Review the clinical trials studying tisagenlecleucel on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-6 of 6

Testing Drug Treatments after CAR T-cell Therapy in Patients with Diffuse Large B-cell Lymphoma That Has Come Back or Not Responded to Treatment
Status: Active
Location: 85 locations
Genetically Modified T-Cells in Treating Patients With Advanced Non-Hodgkin's Lymphoma
Status: Active
Location: 3 locations
Autologous CD22 Chimeric Antigen Receptor (CAR) T cells following Commercial CD19 CAR T cells for the Treatment of Children and Young Adults with Recurrent or Refractory B Cell Acute Lymphoblastic Leukemia
Status: Active
Location: 2 locations
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia, INFLUENCE Trial
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Genetically Modified Cells (CART19) for the Treatment of Pediatric B cell Acute Lymphoblastic Leukemia
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
E7777 to Enhance Regulatory T-Cell Depletion Prior to CAR-T for the Treatment of Relapsed/Refractory B-Cell Lymphomas
Status: Temporarily Closed to Accrual
Location: 2 locations